Here are the 10-K annual reports from Acurx Pharmaceuticals, Inc. (ACXP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals files its annual report describing progress on ibezapolstat, a first‑in‑class oral antibiotic targeting DNA pol IIIC to treat Clostridioides difficile infection (CDI). Phase 2 trials showed a 96% clinical cure rate in 26 treated patients, with rapid eradication of C. difficile and no drug‑related serious adverse events. Microbiome data suggest ibezapolstat preserves beneficial gut bacteria and may lower recurrence compared with vancomycin. The drug holds FDA Qualified Infectious Disease Product and Fast Track designations, supporting an expedited Phase 3 path. Acurx estimates U.S. CDI incidence approaching 600,000 infections annually and projects potential peak‑year sales over $1 billion if approved, reflecting the significant unmet need for recurrence‑reducing CDI therapies.